X Facebook LinkedIn WhatsApp Press Releases (-) Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2018 June 13, 2018 argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation June 11, 2018 argenx to host KOL breakfast symposium on immune thrombocytopenia June 5, 2018 argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis June 4, 2018 argenx selected for BEL 20 Index May 16, 2018 argenx to Present at Upcoming Investor Conferences May 8, 2018 argenx reports first quarter 2018 financial results and provides business update May 7, 2018 argenx announces results of Annual General Meeting of Shareholders April 23, 2018 argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting April 11, 2018 argenx to receive third preclinical milestone payment from collaboration with LEO Pharma April 8, 2018 argenx appoints Keith Woods as Chief Operating Officer April 2, 2018 argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting March 25, 2018 argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe Pagination First page « First Previous page ‹ Previous … Page 14 Page 15 Page 16 Page 17 Current page 18 Page 19 Page 20 Page 21 Page 22 … Next page Next › Last page Last »